Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Adjuvant Cosme JapanLtd

TSE:4929
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4929
TSE
¥7B
Market Cap
  1. Home
  2. JP
  3. Household
Company description

Adjuvant Cosme Japan Co.,Ltd. engages in the research, development, production, and sale of cosmetics in Japan. The last earnings update was 73 days ago. More info.


Add to Portfolio Compare Print
4929 Share Price and Events
7 Day Returns
-2.8%
TSE:4929
-6.6%
JP Personal Products
-8.9%
JP Market
1 Year Returns
-5.3%
TSE:4929
-14.6%
JP Personal Products
-17.9%
JP Market
4929 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Adjuvant Cosme JapanLtd (4929) -2.8% -7.6% -10% -5.3% -1.9% -3.5%
JP Personal Products -6.6% -0.3% -13.3% -14.6% 43% 62.5%
JP Market -8.9% -10.5% -21.9% -17.9% -10.5% -14%
1 Year Return vs Industry and Market
  • 4929 outperformed the Personal Products industry which returned -14.6% over the past year.
  • 4929 outperformed the Market in Japan which returned -17.9% over the past year.
Price Volatility
4929
Industry
5yr Volatility vs Market

4929 Value

 Is Adjuvant Cosme JapanLtd undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Adjuvant Cosme JapanLtd to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Adjuvant Cosme JapanLtd.

TSE:4929 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-12-20) in JPY ¥ 24.000000
Payout Ratio Company Filings (2019-12-20) 5917.4%
Discount Rate (Cost of Equity) See below 5%
Perpetual Growth Rate 10-Year JP Government Bond Rate -0.1%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for TSE:4929
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year JP Govt Bond Rate -0.1%
Equity Risk Premium S&P Global 6.3%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.6
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.596 (1 + (1- 30.86%) (0.31%))
0.73
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.09% + (0.8 * 6.33%)
4.97%

Discounted Cash Flow Calculation for TSE:4929 using Dividend Discount Model Model

The calculations below outline how an intrinsic value for Adjuvant Cosme JapanLtd is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

TSE:4929 Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= ¥24 / (4.97% - -0.09%)
¥473.93
TSE:4929 Discount to Share Price
Calculation Result
Value per share (JPY) From above. ¥473.93
Current discount Discount to share price of ¥882.00
= -1 x (¥882.00 - ¥473.93) / ¥473.93
-86.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Adjuvant Cosme JapanLtd is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Adjuvant Cosme JapanLtd's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Adjuvant Cosme JapanLtd's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSE:4929 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-20) in JPY ¥-22.24
TSE:4929 Share Price ** TSE (2020-04-06) in JPY ¥882
Japan Personal Products Industry PE Ratio Median Figure of 23 Publicly-Listed Personal Products Companies 24.35x
Japan Market PE Ratio Median Figure of 3,071 Publicly-Listed Companies 11.51x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Adjuvant Cosme JapanLtd.

TSE:4929 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4929 Share Price ÷ EPS (both in JPY)

= 882 ÷ -22.24

-39.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Adjuvant Cosme JapanLtd is loss making, we can't compare its value to the JP Personal Products industry average.
  • Adjuvant Cosme JapanLtd is loss making, we can't compare the value of its earnings to the Japan market.
Price based on expected Growth
Does Adjuvant Cosme JapanLtd's expected growth come at a high price?
Raw Data
TSE:4929 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -39.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Japan Personal Products Industry PEG Ratio Median Figure of 12 Publicly-Listed Personal Products Companies 3.38x
Japan Market PEG Ratio Median Figure of 1,281 Publicly-Listed Companies 1.25x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Adjuvant Cosme JapanLtd, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Adjuvant Cosme JapanLtd's assets?
Raw Data
TSE:4929 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-20) in JPY ¥536.67
TSE:4929 Share Price * TSE (2020-04-06) in JPY ¥882
Japan Personal Products Industry PB Ratio Median Figure of 27 Publicly-Listed Personal Products Companies 2.46x
Japan Market PB Ratio Median Figure of 3,576 Publicly-Listed Companies 0.8x
TSE:4929 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4929 Share Price ÷ Book Value per Share (both in JPY)

= 882 ÷ 536.67

1.64x

* Primary Listing of Adjuvant Cosme JapanLtd.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Adjuvant Cosme JapanLtd is good value based on assets compared to the JP Personal Products industry average.
X
Value checks
We assess Adjuvant Cosme JapanLtd's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Adjuvant Cosme JapanLtd has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

4929 Future Performance

 How is Adjuvant Cosme JapanLtd expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Adjuvant Cosme JapanLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
8%
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Adjuvant Cosme JapanLtd expected to grow at an attractive rate?
  • Unable to compare Adjuvant Cosme JapanLtd's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Adjuvant Cosme JapanLtd's earnings growth to the Japan market average as no estimate data is available.
  • Unable to compare Adjuvant Cosme JapanLtd's revenue growth to the Japan market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSE:4929 Future Growth Rates Data Sources
Data Point Source Value (per year)
Japan Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 8%
Japan Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 3.6%
Japan Market Earnings Growth Rate Market Cap Weighted Average 9.1%
Japan Market Revenue Growth Rate Market Cap Weighted Average 3.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSE:4929 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSE:4929 Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
TSE:4929 Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2019-12-20 4,864 -177
2019-09-20 4,769 -251 -278
2019-06-20 4,874 -147
2019-03-20 5,163 94 25
2018-12-20 5,071 70
2018-09-20 5,132 116 197
2018-06-20 5,051 220
2018-03-20 5,097 332 311
2017-12-20 5,033 245
2017-09-20 5,082 521 330
2017-06-20 5,019 306
2017-03-20 4,771 268 330

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Adjuvant Cosme JapanLtd is high growth as no earnings estimate data is available.
  • Unable to determine if Adjuvant Cosme JapanLtd is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSE:4929 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Adjuvant Cosme JapanLtd Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSE:4929 Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
TSE:4929 Past Financials Data
Date (Data in JPY Millions) EPS *
2019-12-20 -22.24
2019-09-20 -34.94
2019-06-20 -18.48
2019-03-20 3.15
2018-12-20 8.83
2018-09-20 24.88
2018-06-20 27.81
2018-03-20 39.32
2017-12-20 30.97
2017-09-20 41.72
2017-06-20 38.69
2017-03-20 41.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Adjuvant Cosme JapanLtd will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Adjuvant Cosme JapanLtd's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Adjuvant Cosme JapanLtd's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Adjuvant Cosme JapanLtd's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Japan market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Japan market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Adjuvant Cosme JapanLtd has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

4929 Past Performance

  How has Adjuvant Cosme JapanLtd performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Adjuvant Cosme JapanLtd's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Adjuvant Cosme JapanLtd does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Adjuvant Cosme JapanLtd's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Adjuvant Cosme JapanLtd's 1-year growth to the JP Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
Adjuvant Cosme JapanLtd's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Adjuvant Cosme JapanLtd Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSE:4929 Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-20 4,864.00 -177.00 3,100.00
2019-09-20 4,769.00 -278.00 3,074.00
2019-06-20 4,874.00 -147.00 3,027.00
2019-03-20 5,163.00 25.00 2,991.00
2018-12-20 5,071.00 70.00 2,880.00
2018-09-20 5,132.00 197.00 2,825.00
2018-06-20 5,051.00 220.00 2,763.00
2018-03-20 5,097.00 311.00 2,700.00
2017-12-20 5,033.00 245.00 2,699.00
2017-09-20 5,082.00 330.00 2,641.00
2017-06-20 5,019.00 306.00 2,613.00
2017-03-20 4,771.00 330.00 2,490.00
2016-12-20 4,642.00 277.00 2,327.00
2016-09-20 4,470.00 234.00 2,273.00
2016-06-20 4,349.00 265.00 2,174.00
2016-03-20 4,401.00 266.00 2,161.00
2015-12-20 4,523.00 75.00 2,188.00
2015-09-20 4,622.00 116.00 2,171.00
2015-06-20 4,574.00 93.00 2,162.00
2015-03-20 4,503.00 47.00 2,136.00
2014-12-20 4,372.00 386.00 2,087.00
2014-09-20 4,449.00 434.00 2,069.00
2014-06-20 4,524.00 501.00 2,025.00
2014-03-20 4,571.00 571.00 1,988.00
2013-12-20 4,493.00 587.00 1,961.00
2013-09-20 4,385.00 526.00 1,918.00
2013-06-20 4,447.00 543.00 1,906.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Adjuvant Cosme JapanLtd has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Adjuvant Cosme JapanLtd has efficiently used its assets last year compared to the JP Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Adjuvant Cosme JapanLtd improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Adjuvant Cosme JapanLtd's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Adjuvant Cosme JapanLtd has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

4929 Health

 How is Adjuvant Cosme JapanLtd's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Adjuvant Cosme JapanLtd's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Adjuvant Cosme JapanLtd is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Adjuvant Cosme JapanLtd's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Adjuvant Cosme JapanLtd's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are -237.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Adjuvant Cosme JapanLtd Company Filings, last reported 3 months ago.

TSE:4929 Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-20 4,274.00 22.00 1,170.00
2019-09-20 4,159.00 27.00 1,125.00
2019-06-20 4,217.00 32.00 1,129.00
2019-03-20 4,549.00 37.00 1,486.00
2018-12-20 4,641.00 42.00 1,654.00
2018-09-20 4,625.00 47.00 1,565.00
2018-06-20 4,502.00 55.00 1,824.00
2018-03-20 4,662.00 64.00 1,894.00
2017-12-20 4,710.00 73.00 1,948.00
2017-09-20 4,568.00 82.00 2,141.00
2017-06-20 4,472.00 91.00 2,378.00
2017-03-20 4,540.00 104.00 2,391.00
2016-12-20 4,641.00 115.00 2,262.00
2016-09-20 4,398.00 165.00 2,440.00
2016-06-20 4,338.00 243.00 2,609.00
2016-03-20 4,441.00 0.00 2,787.00
2015-12-20 4,576.00 0.00 2,526.00
2015-09-20 4,380.00 0.00 2,456.00
2015-06-20 4,286.00 0.00 2,368.00
2015-03-20 4,326.00 0.00 2,360.00
2014-12-20 4,620.00 0.00 2,243.00
2014-09-20 4,400.00 0.00 2,317.00
2014-06-20 4,320.00 0.00 2,380.00
2014-03-20 4,387.00 0.00 2,479.00
2013-12-20 4,308.00 0.00 2,242.00
2013-09-20 4,036.00 0.00 1,997.00
2013-06-20 3,891.00 0.00 1,992.00
  • Adjuvant Cosme JapanLtd's level of debt (-0.3%) compared to net worth is satisfactory (less than 40%).
  • Adjuvant Cosme JapanLtd had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
  • Debt is well covered by operating cash flow (2091.7%, greater than 20% of total debt).
  • Adjuvant Cosme JapanLtd has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Adjuvant Cosme JapanLtd's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Adjuvant Cosme JapanLtd has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

4929 Dividends

 What is Adjuvant Cosme JapanLtd's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.72%
Current annual income from Adjuvant Cosme JapanLtd dividends.
If you bought ¥2,000 of Adjuvant Cosme JapanLtd shares you are expected to receive ¥54 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Adjuvant Cosme JapanLtd's pays a higher dividend yield than the bottom 25% of dividend payers in Japan (1.81%).
  • Adjuvant Cosme JapanLtd's dividend is below the markets top 25% of dividend payers in Japan (4.2%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSE:4929 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Japan Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.5%
Japan Market Average Dividend Yield Market Cap Weighted Average of 2988 Stocks 3%
Japan Minimum Threshold Dividend Yield 10th Percentile 1%
Japan Bottom 25% Dividend Yield 25th Percentile 1.8%
Japan Top 25% Dividend Yield 75th Percentile 4.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSE:4929 Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
TSE:4929 Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-06-14 24.000 2.545
2019-04-19 24.000 2.664
2018-06-15 24.000 2.453
2018-04-20 24.000 2.326
2017-06-16 24.000 2.360
2017-04-21 24.000 2.529
2016-06-17 24.000 2.652
2016-04-22 24.000 2.587
2015-06-18 24.000 2.569
2015-04-24 24.000 2.689
2015-01-23 24.000 2.514
2014-10-24 24.000 2.599
2014-07-25 24.000 2.540
2014-06-19 24.000 2.452
2014-04-24 24.000 2.712
2014-01-24 22.000 2.340
2013-06-18 21.500 2.790
2013-04-18 21.500 3.071
2013-01-18 17.500 2.573

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Adjuvant Cosme JapanLtd has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Adjuvant Cosme JapanLtd only paid a dividend in the past 7 years.
Current Payout to shareholders
What portion of Adjuvant Cosme JapanLtd's earnings are paid to the shareholders as a dividend.
  • The company is paying a dividend however it is incurring a loss.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Adjuvant Cosme JapanLtd's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Adjuvant Cosme JapanLtd afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Adjuvant Cosme JapanLtd has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

4929 Management

 What is the CEO of Adjuvant Cosme JapanLtd's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kenji Matsui
AGE 54
TENURE AS CEO 3.8 years
CEO Bio

Mr. Kenji Matsui has been President and Representative Director of Adjuvant Cosme Japan Co.,Ltd. (a/k/a Adjuvant Kansai Hanbai) since June 16, 2016 and served as its Managing Director since June 2011 and served as its General Manager of Sales Division since October 2010. Mr. Matsui joined Samson & Delila in September 1981 and K.K. Onward Family in May 1992.He joined K.K. Adjuvant Kansai Hanbai May 1995 and served as its Manager of Sales, Sales Promotion Division since March 2004; Executive Officer and General Manager of Sales for Sales Division since March 2007; General Manager of Sales since March 2008; General Manager of Administration Division and General Manager of Business Planning Office since March 2010 and Manager of Hong Kong Branch since June 2011. Mr. Matsui served as a Director of Adjuvant Kansai Hanbai since March 2008.

CEO Compensation
  • Insufficient data for Kenji to compare compensation growth.
  • Insufficient data for Kenji to establish whether their remuneration is reasonable compared to companies of similar size in Japan.
Management Team Tenure

Average tenure and age of the Adjuvant Cosme JapanLtd management team in years:

6.4
Average Tenure
61
Average Age
  • The average tenure for the Adjuvant Cosme JapanLtd management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Kenji Matsui

TITLE
President & Representative Director
AGE
54
TENURE
3.8 yrs

Hideo Nakagawa

TITLE
General Manager of Administration Division
AGE
64
TENURE
9.5 yrs

Sakae Kihara

TITLE
General Manager of Sales Division and Director
AGE
58
TENURE
4.1 yrs

Junko Tanaka

TITLE
Senior Managing Director and Director
AGE
69
TENURE
8.8 yrs
Board of Directors Tenure

Average tenure and age of the Adjuvant Cosme JapanLtd board of directors in years:

6.8
Average Tenure
64
Average Age
  • The tenure for the Adjuvant Cosme JapanLtd board of directors is about average.
Board of Directors

Yutaka Nakamura

TITLE
Chairman of the Board
AGE
73
TENURE
3.8 yrs

Kenji Matsui

TITLE
President & Representative Director
AGE
54
TENURE
3.8 yrs

Hideo Nakagawa

TITLE
General Manager of Administration Division
AGE
64
TENURE
8.8 yrs

Sakae Kihara

TITLE
General Manager of Sales Division and Director
AGE
58
TENURE
8.8 yrs

Junko Tanaka

TITLE
Senior Managing Director and Director
AGE
69

Atsushi Mimura

TITLE
External Director
AGE
41
TENURE
4.8 yrs

Masamitsu Minami

TITLE
Standing Corporate Auditor
AGE
75
TENURE
10.2 yrs

Kiyoshi Kanesaka

TITLE
External Auditor
AGE
74
TENURE
8.8 yrs

Hiroki Nishii

TITLE
External Auditor
AGE
55
TENURE
4.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (¥) Value (¥)
X
Management checks
We assess Adjuvant Cosme JapanLtd's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Adjuvant Cosme JapanLtd has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

4929 News

Simply Wall St News

4929 Company Info

Description

Adjuvant Cosme Japan Co.,Ltd. engages in the research, development, production, and sale of cosmetics in Japan. The company offers skin care products, including cleansing products, face washes, lotions, beauty essences, masks, moisturizing creams, makeup bases, makeups, and body care products; hair care products comprising shampoos, treatments, scalp cleansing products, scalp lotions, and styling products; and other products. It serves hairdressing salons, barber shops, and esthetic salons. The company was founded in 1990 and is headquartered in Kobe, Japan.

Details
Name: Adjuvant Cosme Japan Co.,Ltd.
4929
Exchange: TSE
Founded: 1990
¥7,024,245,354
7,963,997
Website: http://www.adjuvant.co.jp
Address: Adjuvant Cosme Japan Co.,Ltd.
5-5-5, Shimoyamate-dori,
Chuo-ku,
Kobe,
Hyogo, 650-0011,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4929 Common Shares The Tokyo Stock Exchange JP JPY 13. Dec 2012
Number of employees
Current staff
Staff numbers
207
Adjuvant Cosme JapanLtd employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 18:10
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2019/04/19
Last earnings filing: 2020/01/24
Last earnings reported: 2019/12/20
Last annual earnings reported: 2019/03/20


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.